CIRM-Supported Fresno Clinic Earns Cell Therapy Accreditation

In a major step toward bringing cell therapies to patients in California’s Central Valley, Fresno County’s Community Cancer Institute has earned accreditation from the Foundation of Accreditation of Cellular Therapy (FACT).

The milestone follows a $9 million award from the California Institute for Regenerative Medicine (CIRM) last year. CIRM funded a Community Care Center of Excellence (CCCE) at the institute. The new center will give patients in the San Joaquin Valley access to clinical trials, including cell and gene therapy studies.

Expanding Access to Advanced Therapies

The FACT accreditation marks a major validation for the Community Cancer Institute, showing it meets the highest standards. More importantly, it marks another step toward providing access to emerging cell and gene therapies to more than 1 million people who live and work in Fresno and the surrounding counties of Madera, Tulare, Kings, and Merced.

“FACT accreditation is not the end of our journey – it’s the foundation for the next chapter,” said Dr. Haifaa Abdulhaq.

Dr. Abdulhaq is the Director of Cellular Therapy at Community Cancer Institute and Director of Hematology at UCSF Fresno.

“Our goal is to build a comprehensive cellular therapy center that not only delivers currently approved treatments but also brings the next generation of innovative therapies and clinical trials to patients in our region,” she said. “Central Valley patients will have access to the same scientific advances and treatment opportunities available at major academic centers.”

Doctor standing beside a seated patient receiving medical treatment in a clinic room
Dr. Haifaa Abdulhaq with cancer patient Christine Quintero in 2025, who was being treated with CAR T-cell therapy. Photo: Courtesy Community Cancer Institute.

For patients in need of specialized cell therapy, the accreditation means critical treatments are closer to home. Local treatment matters for people who would otherwise have to drive hours to clinics at UC San Francisco, UC Davis, or Stanford Medical Center. The Community Cancer Institute is located within the Clovis Community Medical Center.

The clinic is now part of CIRM’s Clinical Care Network, which includes three other CCCEs and nine Alpha Clinics, distributed across California. The CCCEs are part of CIRM’s Clinical Infrastructure program, which also includes Alpha Clinics and a Patient Support Program, which together help Californians find, enroll, and participate in clinical trials.

Building Clinical and Manufacturing Capacity

Cell and gene therapies demand more than clinical space. They require specialized staff, evidence-based care, and facilities equipped to deliver treatment safely. CAR T-cell therapy, for example, engineers a patient’s immune cells to fight cancer.

To earn accreditation, Community Cancer Institute adopted a multidisciplinary approach and partnered with teams at UCSF Fresno and the University of California, Davis.

The institute’s next goal is a local cell-processing and Good Manufacturing Practice (GMP) facility. Leaders aim to open the facility in late 2027 to support research and manufacturing.